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Introduction: Advanced thymoma (stage III and IV) is difficult to 
detect by computed tomography (CT), yet it is important to distin-
guish between early (stage I and II) and advanced disease before 
surgery, as patients with locally advanced tumors require neoadju-
vant chemotherapy to enable effective resection. This study assessed 
whether the amount of fluorodeoxyglucose (FDG) uptake can predict 
advanced thymoma and whether it can separate thymoma from thy-
mic cancer.
Methods: We retrospectively reviewed FDG positron emission 
tomography (PET)-CT scans of 51 consecutive newly diagnosed 
patients with thymic epithelial malignancy. PET-CT findings docu-
mented focal FDG activity: SUV
max
, SUV
mean
, SUV
peak
, and total 
body volumetric standardized uptake value (SUV) measurements. 
These were correlated with Masaoka–Koga staging and World Health 
Organization classification. Wilcoxon ranked sum tests were used to 
assess association between SUV and pathological stage, cancer type, 
and classification.
Results: Among the study patients, 37 had thymoma, 12 thymic car-
cinoma, and 2 thymic carcinoid. Higher focal FDG uptake was seen 
in patients with type B3 thymoma than in those with type A, AB, B1, 
or B2 thymoma (p < 0.006). FDG uptake was higher in patients with 
thymic carcinoma or carcinoid than in patients with thymoma (p < 
0.0003), with more variable associations with volumetric SUV mea-
surements. There was no significant association observed between 
higher focal FDG uptake and advanced-stage disease in thymoma 
patients (p > 0.09), although greater FDG-avid tumor volume was 
significantly associated with advanced disease (p < 0.03).
Conclusions: Focal FDG uptake cannot predict advanced thymoma 
but is helpful in distinguishing thymoma from thymic carcinoma, or 
the more aggressive thymoma, type B3.
Key Words: Thymoma, PET-CT, Masaoka–Koga.
(J Thorac Oncol. 2013;8: 502-510)
Thymic epithelial neoplasms include thymoma, thymic carcinoma, and carcinoid. Of these, thymoma is the most 
common and accounts for approximately 20% of adult anterior 
mediastinal neoplasms.1 Computed tomography (CT) is the 
most common imaging modality currently used for evaluation 
of the anterior mediastinal mass. However, often, it cannot dif-
ferentiate early (stage I and II) from advanced (stage III and 
IV) disease, as local invasion into the pericardium and vessels 
is more difficult to appreciate than simple abutment, and fine 
pleural metastatic spread may be below the resolution of CT. 
It is important to distinguish between early and advanced dis-
ease before surgery, as patients with locally advanced tumors 
receive neoadjuvant chemotherapy to enable effective resec-
tion.2 Complete resection, even of advanced disease, improves 
survival.3
Some surgeons advocate thymectomy without biopsy 
for small anterior mediastinal masses suggestive of thymoma. 
However, early-stage thymoma, thymic cancer, and carcinoid 
may look identical on CT. As thymic cancer and thymic car-
cinoid are much more aggressive than thymoma, with a ten-
dency for early metastatic spread, patients with these tumors 
usually receive neoadjuvant chemotherapy, even with clini-
cal early disease. Therefore, identifying the specific disease 
before thymectomy is desirable for the betterment of therapy.
Fluorine-18 fluorodeoxyglucose (FDG) positron emi ssion 
tomography (PET)-CT has emerged as a strong diagnostic tool 
for the diagnosis, clinical staging, and outcome of intrathoracic 
malignancies, especially in patients with non–small-cell lung 
cancer,4,5 but the precise role of FDG PET-CT in the management 
of thymic epithelial malignancies, especially thymoma, is 
unclear. There is controversy about FDG PET-CT’s ability to 
differentiate between invasive and noninvasive thymomas, and 
only a few small studies have assessed FDG-PET imaging of 
thymoma, the majority of which also combined thymic cancers 
in their evaluation.6,7
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The goal of our study was to assess whether FDG 
PET-CT can distinguish thymoma from thymic carcinoma and 
carcinoid and whether it can distinguish early from advanced 
thymoma, for which preoperative chemotherapy is needed.
PATIENTS AND METHODS
Patients
A retrospective search of a PET-CT database from The 
University of Texas MD Anderson Cancer Center revealed 140 
patients who were referred for FDG PET-CT scanning for the 
evaluation of thymic epithelial neoplasms between October 
2003 and November 2011. Of the 140 patients referred for 
thymic epithelial neoplasm evaluation based on their PET-CT 
scans, 89 patients were excluded because no pretreatment 
PET-CT was available for review. Therefore, the final study 
group comprised 51 patients for whom a pretreatment PET-CT 
for evaluation of a thymic epithelial malignancy was avail-
able for review. We reviewed these patients’ computerized 
medical records to extract demographic data, their operative, 
pathology, treatment reports, and their imaging studies. This 
study was approved by our institutional review board and we 
obtained a waiver of the requirement for informed consent. In 
addition, our study was in compliance with Health Insurance 
Portability and Accountability Act regulations.
Staging
We applied the Masaoka–Koga staging system8 to each 
case by reviewing the operative and pathology reports in con-
sultation with an experienced pathologist specializing in thy-
moma (C.A.M.). This staging system is based on gross and 
microscopic properties of the tumor, where stage I was assigned 
when the tumor was completely encapsulated; stage II was 
assigned when there was either microscopic invasion into the 
capsule (IIa) or invasion into surrounding fat (IIb); stage III was 
assigned when there was invasion into a neighboring organ such 
as the pericardium, great vessels, or lung; and stage IV was 
assigned when there was pleural or pericardial dissemination 
(IVa) or lymphatic/hematogenous metastasis (IVb). The WHO 
classification9 for each tumor was determined (by CAM) from 
the operative specimen and was dichotomized into atypical thy-
moma (WHO type B3) and typical thymoma (WHO type A, 
AB, B1, and B2) for statistical purposes. Similarly, for statisti-
cal purposes, carcinoid was included with thymic carcinoma.
PET-CT
Integrated PET-CT systems were used to acquire imaging 
data (Discovery ST, STe, or RX; General Electric Healthcare, 
Waukesha, WI). Whole-body examinations were performed 
from the level of the vertex of the skull or orbits through the 
upper thighs. PET-CT was performed in accordance with 
guidelines published by the National Cancer Institute.10 All 
patients fasted for a minimum of 6 hours before the intrave-
nous injection of FDG. A normal fasting blood glucose level 
of 80–120 mg/dl (4.4–6.6 mmol/l) was a standard requirement 
for imaging in all patients. PET data acquisition was performed 
in 2D mode before January 2008 and was changed to 3D mode 
after that date. For 2D imaging, an intravenous injection of 555 
to 629 MBq (15–17 mCi) of FDG was administered in the arm 
or central venous catheter on the side opposite the cancer, and 
emission scans were acquired at 3 minutes per field of view 
60–90 minutes after the FDG injection. The same procedure 
was used for 3D imaging except for using an injected dose 
of 333 to 407 MBq (9–11 mCi) of FDG. PET images were 
reconstructed using standard vendor-provided reconstruction 
algorithms. Noncontrast-enhanced CT images were acquired 
in helical mode (speed, 13.5 mm/rotation) from the base of 
the skull to the midthigh during suspended midexpiration at 
a 3.75-mm slice thickness, a tube voltage of 120 kVp, a tube 
current–time product of 150 mAs, and a 0.5-second rotation. 
Attenuation-corrected and nonattenuation-corrected datasets 
were reconstructed.
The PET-CT scans were reviewed by two experienced 
chest radiologists (M.F.K.B. and E.M.M.) who were blinded 
to clinical information. Differences in their findings were 
resolved by consensus. Imaging findings were recorded for 
each patient. A clinical CT stage was assigned and FDG 
uptake was recorded in terms of standardized uptake value 
body weight (SUV) as SUV
max
, SUV
mean
, or SUV
peak
. Total 
body volumetric SUV was calculated as the volume of tumor 
(in cm3) within 45% of SUV
max
, and the volume of tumor (in 
cm3) with SUV
max
 above a threshold of 3.5. For these measure-
ments SUV
mean
 and SUV
peak
 were determined from the volume 
of interest defined by the 45% of the SUV
max
.
Statistical Analysis
We used Wilcoxon ranked sum tests to assess asso-
ciations between SUV and pathological stage, cancer type, 
and WHO classification, with p values computed using the 
normal approximation. We used Fisher’s exact test to assess 
association between cancer type and pathological stage. We 
calculated overall survival (OS) from the date of the initial 
pathology diagnosis todate of death or last follow-up. We cal-
culated progression-free survival from the date of the initial 
pathology diagnosis to first progression, death, or last clinical 
evaluation for progression. We used univariate Cox regression 
models to predict OS and progression-free survival time from 
SUV measurements. All statistical analyses were performed 
using SAS 9.2 for Windows (SAS Institute Inc., Cary, NC).
RESULTS
Patient and Disease Characteristics
Among the 51 study patients, 37 patients had a pathology 
diagnosis of thymoma, 12 patients had thymic carcinoma, and 
two patients had thymic carcinoid. Thirty patients (59%) were 
TABLE 1.  Association Between Cancer Type and Pathology 
Stage
Pathological stage
I–II III–IV
WHO Count % Count % Total p Value
Thymoma 20 54 17 46 37
0.0033
Thymic carcinoma, carcinoid 1 7 13 93 14
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men and 21 patients (41%) were women. Their ages ranged 
from 21 to 84 years (mean: 59.4 years). Using the Masaoka–
Koga pathological staging for the thymoma patients, 1 
patient (3%) had stage I disease, 14 patients (37%) had stage 
IIa disease, five patients (13%) had stage IIb disease, eight 
patients (22%) had stage III disease, seven patients (19%) 
had stage IVa disease, and two patients (6%) had stage IVb 
disease. Among the 14 patients with thymic carcinoma or 
thymic carcinoid, one patient (7%) had stage I disease, six 
patients (43%) had stage III disease, three patients (21%) 
had stage IVa disease, and four patients (29%) had stage IVb 
disease. Patients with thymoma were more likely to present 
with early-stage disease (n = 20; 54%) than were patients 
with thymic carcinoma and carcinoid (n = 1; 7%) (p = 0.003) 
(Table 1). Of the 37 thymoma patients, surgical specimens for 
36 were available for histological classification review. Most 
were confirmed to have typical thymoma: WHO classification 
type A in eight patients (22%), type AB in three patients (8%), 
type B1 in 10 patients (27%), and type B2 in nine patients 
(24%); only seven patients (19%) presented with atypical 
thymoma (type B3) (Table 2).
PET-CT and Tumor Classification
The FDG uptake of thymic carcinoma and thymic car-
cinoid was significantly higher than that of thymoma, as mea-
sured by SUV
max
 (p = 0.0001), SUV
peak
 (0.0003), SUV
mean
 
(0.0001), and total tumor volume above SUV
max
 3.5 (p = 0.02), 
but not by volumetric measurement calculated as total tumor 
volume, within 45% of SUV
max
 (p = 0.74) (Table 3) (Figs. 
1–3). Using an SUV
max
 value of 6 or more to classify everything 
TABLE 3.  Association Between SUV and Cancer Type
SUV
Cancer type
Thymoma (n = 37) Thymic cancer, carcinoid (n = 14)
Mean (SD) Range Mean (SD) Range p Value
Primary tumor SUV
max
6.27 (4.18) 1.50–25.20 11.09 (5.48) 6.00–25.70 0.0001
Primary tumor SUV
peak
5.53 (3.84) 1.50–23.20 9.38 (4.61) 5.00–20.20 0.0003
Primary tumor SUV
mean
3.85 (2.53) 1.00–15.20 6.72 (3.15) 3.50–15.00 0.0001
Total tumor volume of SUV 45% (cm3) 176.31 (247.31) 6.10–1076.00 153.71 (147.31) 4.00–532.50 0.7435
Total volume above SUV 3.5 (cm3) 139.29 (280.33) 0.00–1378.20 203.01 (188.32) 6.10–579.00 0.0212
SUV, standardized uptake value.
TABLE 2.  Masoka–Koga Staging Compared with the WHO 
Histologic Classification System for Patients with Thymoma
Masaoka–Koga staging
I II III IV
WHO Count % Count % Count % Count % Total
A 1 12.5 4 50 3 37.5 0 0 8
AB 0 0 3 100 0 0 0 0 3
B1 1 11 5 56 1 11 2 22 9
B2 0 0 3 33 2 22 4 44 9
B3 1 14 2 29 2 29 2 29 7
Total 3 8 17 47 8 22 8 22 36
FIGURE 1.  Fifty-four-year-old man with thymic carcinoma. Axial contrast-enhanced CT (A) at the level of the left pulmonary 
artery (L) demonstrated a large heterogeneous anterior mediastinal mass (arrows) surrounding 180° of the circumference of the 
ascending aorta (Ao). The coronal maximum intensity projection FDG PET image (B) and fused PET-CT image (C) show intense 
FDG uptake within the mass, with an SUVmax of 14.1 (arrow). Note that mild FDG uptake in a right hilar lymph node (arrow 
head), which biopsy proved to represent a lymph node metastasis, yielding a diagnosis of stage IVb disease. CT, computed 
tomography; FDG, fluorodeoxyglucose; PET, positron emission tomography; SUV, standardized uptake value.
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above this as thymic cancer/carcinoid, 100% of thymic can-
cer/arcinoid tumors were correctly identified but 38% of thy-
moma patients were classified as thymic cancer. A value of 7 or 
more misclaffied thymic cancer as thymoma, whereas a value 
of five resulted in 59% of thymomas misclassified as thymic 
cancer. When assessing whether FDG uptake differentiated 
between the different thymoma WHO classification types, we 
found that higher FDG uptake did distinguish B3 thymoma 
from the other types combined when FDG uptake was mea-
sured in terms of SUV
max
 (p = 0.006), SUV
peak
 (p = 0.004), and 
SUV
mean
 (p = 0.005), and total tumor volume above SUV
max
 3.5 
(p = 0.04) (Figs. 4 and 5), but not when it was recorded as 
the volumetric measurement calculated as total tumor volume 
within 45% of SUV
max
 (p = 0.78) (Table 4). When trying to 
differentiate thymoma WHO types B2 and B3 from types A, 
AB, and B1, we found a weak association only for total tumor 
volume measurement above SUV
max
 3.5 (p = 0.05), not for the 
other SUV measurements (p > 0.08) (Table 5).
PET-CT and Tumor Staging
FDG uptake was higher for patients with epithelial thy-
mic malignancies presenting with advanced disease (Table 6) 
(p < 0.01) than for patients with early-stage disease. However, 
when excluding thymic carcinoma and thymic carcinoid and 
assessing the association of FDG uptake with the Masaoka–
Koga stage for thymomas only, there was no association 
between higher FDG activity and advanced disease measured 
by SUV
max
 (p = 0.135), SUV
peak
 (p = 0.097), and SUV
mean
 (p 
= 0.206) (Figs. 2 and 6). Greater volumes of FDG-avid tumor 
did correlate with advanced stage, as measured by tumor vol-
ume above 45% of SUV
max
 (p = 0.002), and tumor volume 
above SUV
max
 3.5 (p = 0.029) (Table 7).
Because of the clinical need to distinguish patients who 
have clinical Masaoka–Koga stage early disease from those 
who have locally advanced disease (stage III) at the time of 
initial staging CT, we also assessed whether the FDG uptake 
could differentiate early from advanced disease in our patient 
group. In this group of patients with clinical stage I–III epi-
thelial thymic malignancies, the amount of FDG uptake, 
whether measured as SUV
max
, SUV
mean
, or SUV
peak
 or whether 
measured volumetrically, could not stratify patients into the 
groups defined by disease stage (p = 0.078–0.183). Similar 
results were seen when evaluating only the patients with clini-
cal stage I–III thymoma: the amount of FDG uptake, whether 
measured as SUV
max
, SUV
mean
, or SUV
peak
 or measured volu-
metrically, could not stratify patients into early and advanced 
disease groups (p = 0.21–0.93) (Table 8).
PET-CT and Outcome
Follow-up medical information was available for 50 
of the 51 patients who presented with a thymic epithelial 
malignancy. Patients were followed for a median of 942 days 
FIGURE 2.  Forty-one-year-old man complaining of chest pain for 1 week. (A) Axial image from contrast-enhanced chest CT 
at the level of the right pulmonary artery (R) revealed a 5-cm anterior mediastinal mass with central calcifications (arrow). (B) 
Axial image caudal to A, at the level of the right ventricle (RV), demonstrates a lentil-shaped pleural nodule, typical for a pleural 
metastasis. Surgery confirmed a type B2, stage IVa thymoma. (C) Fused FDG PET-CT image shows mild FDG uptake in the ante-
rior mediastinal mass with SUVmax of 3.8 (arrow). CT, computed tomography; FDG, fluorodeoxyglucose; PET, positron emission 
tomography; SUV, standardized uptake value.
FIGURE 3.  Box and whisker plot stratified by thymoma  
(n = 37) versus thymic cancer/carcinoid (n = 14) demonstrat-
ing a significant difference in primary tumor SUVmax (p = 
0.0001). Observations above the upper fence, defined as 1.5 
IQR above the 75th percentile, are displayed as squares. The 
middle black line in box represents the median. The blue dot 
represents the mean.
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(ranges,139–3801 days). Fourteen patients had progression of 
disease and seven patients died. FDG uptake was not a pre-
dictor of progression-free survival time (p > 0.12) nor of OS 
(p > 0.06).
Follow-up medical information was available for all 37 
patients who presented with thymoma. They were followed-
up for a median of 1049 days (ranges, 139–3801 days). Six 
patients had progression of disease and two patients died. 
FDG uptake could neither be used as a valid predictor of pro-
gression-free survival (p > 0.11) nor of OS (p > 0.10).
DISCUSSION
Our study has shown that higher FDG uptake is asso-
ciated with the more aggressive forms of thymic epithelial 
malignancies, thymic carcinoma, and thymic carcinoid, but it 
has also shown that focal FDG uptake cannot distinguish early 
from advanced disease in patients presenting with thymoma.
Thymoma is more common but carries a better 
prognosis than thymic carcinoma.11 Studies assessing the use 
of FDG PET in thymic epithelial malignancies have been 
small, reviewing from 10 to 49 patients only.12 Early results 
consistently showed that FDG uptake as measured by SUV
max
 
was much higher in thymic carcinoma than in thymoma, a 
finding supported by our study as well,7,13–18 and correlates 
with the more aggressive nature of thymic carcinoma.
Our study has also shown that the user-friendly point of 
maximal FDG uptake, SUV
max
, available on any workstation, 
or the SUV
peak
 found on some workstations, correlated 
better with histology than the more cumbersome volumetric 
measurements. This finding is useful for treatment planning 
for patients presenting with smaller masses suggestive of 
thymic epithelial malignancy because there are surgeons who 
advocate resection of such masses without preoperative biopsy 
confirmation. This could be problematic in cases of thymic 
cancer, for which neoadjuvant chemotherapy is commonly 
used because of the cancer’s aggressiveness and in cases of 
FIGURE 4.  Twenty-nine-year-old woman complaining of chest pain over the last year. Contrast-enhanced chest CT image (A) 
at the level of the left pulmonary artery (L) demonstrates a large anterior mediastinal mass (M) deforming and surrounding the 
superior vena cava (*) for more than 180° of its circumference. Coronal maximum intensity projection FDG PET image (B) and 
fused axial PET-CT show the mass was intensely FDG avid, with a SUVmax of 15.5. Surgery confirmed a type B3 thymoma, stage 
IVa. The tumor directly involved the pericardium, superior vena cava, and right upper lobe, and there were small pleural metas-
tases. CT, computed tomography; FDG, fluorodeoxyglucose; PET, positron emission tomography; SUV, standardized uptake 
value.
FIGURE 5.  Box and whisker plot of thymoma only patients 
stratified by WHO classification A-B2 (n = 29) versus B3 (n = 7)  
demonstrating a significant difference in primary tumor SUVmax 
(p = 0.0062). Observations above the upper fence, defined as 
1.5 IQR above the 75th percentile, are displayed as squares. 
The middle black line in box represents the median. The blue 
dot represents the mean.
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nonsurgical/hematological malignancies such as lymphoma. 
Knowing the FDG uptake can help navigate patients to the 
correct treatment plan. Patients with lower FDG uptake would 
be presumed to have thymoma and would require surgery, 
whereas those with higher FDG uptake would have a biopsy 
performed to test for either thymic cancer or lymphoma.18,19 
Although we found the best value for this approach to be 
SUV
max
 value of 6 or more, this should be interpreted with 
caution, as a similar study found the best value to be SUV
max
 
value of 5 or more.19 FDG uptake quantification is affected by 
many technical factors which vary from one institution to the 
other and is affected by physiologic factors which can alter the 
SUV by more than 50%.20
Imaging studies so far have used a simplified system 
of low-risk (type A, AB, and B1) thymoma and compared 
them to high-risk (type B2 and B3) thymomas, but this has 
produced variable results. Two studies showed that FDG PET 
helped differentiate low-risk from high-risk thymoma (type 
B2 and B3),14,18 whereas two other studies showed that it did 
not.7,15 Because of these variable results, we sought to deter-
mine whether a different simplification of the WHO system, 
separating type B3 from the more indolent forms of thymoma, 
would better correlate with FDG uptake.21 We chose this form 
of classification in view of a recent study that assessed 250 
thymoma patients and showed that type B3 thymoma has a 
significantly worse prognosis than the other types.22,23 Indeed, 
in our study, FDG uptake was much higher when type B3 was 
separated from types A through B2. This is of clinical impor-
tance, not only for those patients who do not routinely undergo 
a biopsy procedure before surgery but also for those who do, 
TABLE 4.  Association Between SUV and WHO Classification Type (Thymoma Only)
SUV
WHO classification
p Value
A-B2 (n = 29) B3 (n = 7)
Mean (SD) Range Mean (SD) Range
Primary tumor SUV
max
5.57 (4.07) 1.50–25.20 9.14 (3.91) 5.00–15.50 0.0062
Primary tumor SUV
peak
4.89 (3.77) 1.50–23.20 8.14 (3.51) 4.60–14.00 0.0040
Primary tumor SUV
mean
3.42 (2.47) 1.00–15.20 5.60 (2.34) 3.10–9.70 0.0054
Total tumor volume of SUV 45% (cm3) 166.41 (257.12) 6.10–1076.00 171.79 (202.49) 10.80–564.50 0.7796
Total volume above SUV 3.5 (cm3) 113.45 (279.90) 0.0–1378.20 220.31 (299.14) 6.70–773.20 0.0408
SUV, standardized uptake value.
TABLE 5.  Association Between SUV and WHO Classification Type (Thymoma Only)
SUV
WHO classification
p Value
A-B1 (n = 20) B2,B3 (n = 16)
Mean Range Mean Range
Primary tumor SUV
max
4.96 (1.35) 2.60–7.30 7.90 (5.86) 1.50–25.20 0.1077
Primary tumor SUV
peak
4.32 (1.23) 2.60–6.80 7.03 (5.40) 1.5–23.20 0.0798
Primary tumor SUV
mean
3.06 (0.93) 1.60–5.10 4.83 (3.52) 1.0–15.2 0.0882
Total tumor volume of SUV 45% (cm3) 103.95 (102.30) 6.20–341.90 246.84 (338.33) 6.10–1076.0 0.3159
Total volume above SUV 3.5 (cm3) 38.89 (65.09) 0.0–235.4 253.41 (392.03) 0.0–1378.2 0.0532
SUV, standardized uptake value.
TABLE 6.  Association Between SUV and Pathology Stage (All Patients)
SUV
Stage
p Value
I+II (n = 21) III+IV (n = 30)
Mean (SD) Range Mean (SD) Range
Primary tumor SUV
max
5.44 (2.52) 1.50–12.70 9.10 (5.76) 3.80–25.70 0.0053
Primary tumor SUV
peak
4.69 (2.11) 1.50–10.70 7.91 (5.05) 3.20–20.20 0.0037
Primary tumor SUV
mean
3.43 (1.60) 1.00–7.10 5.48 (3.42) 2.40–15.00 0.0106
Total tumor volume of SUV 45% (cm3) 70.71 (81.41) 6.10–341.90 239.69 (262.87) 12.00–1076.00 0.0010
Total volume above SUV 3.5 (cm3) 37.06 (61.80) 0.00–235.40 240.59 (307.56) 0.90–1378.20 0.0008
SUV, standardized uptake value.
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as thymoma is a heterogeneous tumor and a biopsy does not 
always sample the most aggressive part of it. Therefore, the 
FDG uptake could be used to direct those patients with a worse 
prognosis towards neoadjuvant therapy, whether they are part 
of the high-risk thymoma group (type B3) or the thymic car-
cinoma group.24–26 This is also useful as type B3 thymoma and 
thymic carcinoma have been shown in larger studies to usually 
present with advanced (stage III or IV) disease.24–26
In thymoma, the separation of early disease from 
advanced disease, the latter of which requires neoadjuvant 
therapy, is the most important goal in this clinical staging. 
Because most stage III thymomas do not present with direct 
signs of invasion on morphological imaging (CT or magnetic 
resonance imaging), recognizing locally advanced disease is 
challenging and often relies on indirect signs rather than the 
visualization of the invasion itself.27 Having a physiological 
marker to help in the differentiation of advanced disease 
would be helpful. Unfortunately, we found that none of the 
volumetric FDG uptake metrics we assessed were helpful in 
separating early from advanced disease. We chose to assess 
FDG as measured by both SUV
max
 and SUV
peak
 because 
SUV
max
 is the method that is used most often for evaluating 
FDG uptake and is currently available on all commercially 
available PET-CT workstations. Because SUV
max
 is based on 
a single voxel value, its reproducibility is not as good as that 
of SUV
peak
, which assesses a volume of approximately 1 cm3 
around the area of maximal FDG uptake.28 Our study is in 
agreement with another investigation17 that confirmed the 
inability of FDG SUV
max
 to predict thymoma invasiveness. For 
many cancers, there is an ongoing fundamental debate about 
whether tumor prognosis and response to therapy are best 
evaluated by measuring tumor volume or by quantifying the 
most metabolically active portion of the tumor.29–34 It is for this 
reason that we chose to measure FDG’s highest focal activity 
and its total metabolic volume. Of note, higher volumes of 
metabolic tumor did correlate with advanced disease. This, 
however, may have been because of the tumor size itself rather 
than its metabolic activity, as larger tumors are known to be 
associated with higher stages of disease.27 When patients with 
obvious clinical stage IV disease were excluded from this 
analysis, however, the association between total metabolic 
volume and advanced disease was no longer preserved, 
showing that, for thymic epithelial tumors, cumbersome 
volumetric measurements are probably not worthwhile.
The presence of higher FDG uptake in many tumors has 
been shown to be associated with a worse outcome, regardless 
of stage.35–39 We could not find such an association for thymic 
epithelial malignancies in our study. It remains to be seen if 
FDG uptake will prove useful for monitoring the response of 
nonresectable thymic epithelial malignancies. A preliminary 
FIGURE 6.  Box and whisker plot of thymoma only patients 
stratified by pathologic stage I/II (n = 20) versus III/IV (n = 17)  
demonstrating no significant difference in primary tumor 
SUVmax (p = 0.1351). Observations above the upper fence, 
defined as 1.5 IQR above the 75th percentile, are displayed as 
squares. The middle black line in box represents the median. 
The blue dot represents the mean.
TABLE 7.  Association Between SUV and Pathological Stage (Thymoma Only)
SUV
Stage
p-value
I+II (n = 20) III+IV (n = 17)
Mean (SD) Range Mean (SD) Range
Primary tumor SUV
max
5.26 (2.44) 1.50–12.70 7.46 (5.42) 3.80–25.20 0.1351
Primary tumor SUV
peak
4.58 (2.10) 1.50–10.70 6.65 (5.05) 3.20–23.20 0.0966
Primary tumor SUV
mean
3.29 (1.50) 1.00–7.10 4.51 (3.29) 2.40–15.20 0.2055
Total tumor volume of SUV 45% (cm3) 74.04 (82.04) 6.10–341.90 296.63 (318.08) 28.00–1076.00 0.0022
Total volume above SUV 3.5 (cm3) 38.61 (62.99) 0.00–235.40 257.74 (380.16) 0.00–1378.20 0.0288
SUV, standardized uptake value.
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study of a subgroup of patients with nonresectable thymic epi-
thelial malignancies has shown that OS was longer for those 
patients who had partial metabolic responses to treatment than 
for those who did not.40
Our study’s main limitations relate to its retrospective 
nature and the small number of patients evaluated. However, 
it represents the largest series published so far of patients with 
this studied rare disease.12 In addition, many prior studies 
have analyzed mixed populations of patients with thymic 
carcinoma and thymoma, creating difficulties in drawing 
conclusions that might be implemented into daily clinical use. 
We thus deliberately analyzed thymoma patients separately 
from thymic carcinoma patients so that our findings could 
inform daily clinical decision making.
In conclusion, although FDG PET-CT is an excellent 
tool for the assessment of the patient presenting with an ante-
rior mediastinal mass and can be used to differentiate thymic 
carcinoma from thymoma, FDG uptake is not helpful in deter-
mining the disease stage. Thus for the time being, this imaging 
modality is reserved for detecting those patients more likely 
to require preoperative chemotherapy, such as patients with 
thymic carcinoma or the more aggressive type of thymoma, 
type B3.
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